260 related articles for article (PubMed ID: 20085555)
1. The effect of sertindole on QTD and TPTE.
Nielsen J; Andersen MP; Graff C; Kanters JK; Hardahl T; Dybbro J; Struijk JJ; Meyer JM; Toft E
Acta Psychiatr Scand; 2010 May; 121(5):385-8. PubMed ID: 20085555
[TBL] [Abstract][Full Text] [Related]
2. Sertindole causes distinct electrocardiographic T-wave morphology changes.
Nielsen J; Graff C; Hardahl T; Andersen MP; Kristoffersen J; Struijk JJ; Toft E; Meyer JM
Eur Neuropsychopharmacol; 2009 Oct; 19(10):702-7. PubMed ID: 19457646
[TBL] [Abstract][Full Text] [Related]
3. Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia.
Nielsen J; Matz J; Mittoux A; Polcwiartek C; Struijk JJ; Toft E; Kanters JK; Graff C
Eur Neuropsychopharmacol; 2015 Mar; 25(3):303-11. PubMed ID: 25583364
[TBL] [Abstract][Full Text] [Related]
4. Effect of sertindole on QTc interval in patients with schizophrenia.
Atmaca M; Yavuzkir M; Mermi O; Topuz M; Kanmaz E; Tezcan E
Neurosci Lett; 2008 Sep; 442(1):1-3. PubMed ID: 18639380
[TBL] [Abstract][Full Text] [Related]
5. Drug safety and efficacy evaluation of sertindole for schizophrenia.
Karamatskos E; Lambert M; Mulert C; Naber D
Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
[TBL] [Abstract][Full Text] [Related]
6. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
8. [Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].
Gury C; Canceil O; Iaria P
Encephale; 2000; 26(6):62-72. PubMed ID: 11217540
[TBL] [Abstract][Full Text] [Related]
9. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole.
Lindström E; Farde L; Eberhard J; Haverkamp W
Int J Neuropsychopharmacol; 2005 Dec; 8(4):615-29. PubMed ID: 15963244
[TBL] [Abstract][Full Text] [Related]
10. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
11. The safety of atypical antipsychotics: does QTc provide all the answers?
Nielsen J
Expert Opin Drug Saf; 2011 May; 10(3):341-4. PubMed ID: 21504386
[TBL] [Abstract][Full Text] [Related]
12. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
13. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
Milic M; Bao X; Rizos D; Liu F; Ziegler MG
Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
[TBL] [Abstract][Full Text] [Related]
14. Sulpiride induced torsade de pointes.
Huang BH; Hsia CP; Chen CY
Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
[TBL] [Abstract][Full Text] [Related]
15. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
[TBL] [Abstract][Full Text] [Related]
16. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.
Pezawas L; Quiner S; Moertl D; Tauscher J; Barnas C; Küfferle B; Wolf R; Kasper S
Int Clin Psychopharmacol; 2000 Jul; 15(4):207-14. PubMed ID: 10954060
[TBL] [Abstract][Full Text] [Related]
18. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe.
Lançon C; Toumi M; Sapin C; Hansen K
BMC Psychiatry; 2008 Jul; 8():57. PubMed ID: 18638382
[TBL] [Abstract][Full Text] [Related]
19. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma.
Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Nousiainen T; Hartikainen J
Clin Physiol Funct Imaging; 2010 May; 30(3):175-80. PubMed ID: 20132128
[TBL] [Abstract][Full Text] [Related]
20. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
